During late-stage sepsis, TIGIT-expressing Foxp3+ Tregs exhibit enhanced suppressive function dependent on the IL-33/ST2/STAT6/M2 macrophage axis, suggesting that IL-33 or anti-TIGIT therapy may represent a promising strategy for the treatment of immunosuppressive sepsis [85,86]. The gene discussed is IL33; the disease is Sepsis.